{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"1"}]}],"title":"Complete Response (CR)"},{"categories":[{"measurements":[{"groupId":"OG001","value":"0"}]}],"title":"Partial Response (PR)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"description":"Complete Response (CR):\n\n* No measurable or nonmeasurable disease.\n* No symptoms of Lymphoma.\n* Non-palpable spleen, if palpable at baseline.\n* Histologically negative bone marrow, if positive at baseline.\n* All nodes \\<1.5 cm in transverse diameter.\n\nPartial Response (PR):\n\n* greater than 50% decrease from baseline in the sum of the products of the longest perpendicular diameters of the six largest dominant lesions.\n* No new lesions\n\nWe are reporting the number of participants that attained a status of CR or PR.","groups":[{"description":"Phase I patients will receive the following treatment:\n\n* 250 mg/m\\^2 Rituximab IV on days 1, 8, and 15 of a 27 day cycle\n* 5 mCi (Indium-111), 1.6 mg Ibritumomab IV on day 1\n* 10 mCi (Indium-111), 1.6 mg Ibritumomab IV on day 8\n* CpG 7909 (Agatolimod Sodium) doses will be assigned in groups of 6 patients. Dose levels will escalate in each group until maximum tolerability is attained (starting at 0.08 mg/kg and sequentially escalating to 0.16 mg/kg, 0.32 mg/kg, 0.48 mg/kg). Doses will be taken day 6, 13, 20, and 27 of a 27 day cycle.\n* 0.4 mCi/kg Yttrium-90 Zevalin IV on day 15","id":"OG000","title":"Phase I"},{"description":"Phase II patients will receive the following treatment:\n\n* 250 mg/m\\^2 Rituximab IV on days 1, 8, and 15 of a 27 day cycle\n* 5 mCi (Indium-111), 1.6 mg Ibritumomab IV on day 8\n* 0.48 mg/kg CpG 7909 (Agatolimod Sodium) doses will be taken day 6, 13, 20, and 27 of a 27 day cycle.\n* 0.4 mCi/kg Yttrium-90 Zevalin IV on day 15","id":"OG001","title":"Phase II"}],"paramType":"NUMBER","populationDescription":"Participants accrued to the Phase I portion of this study were not used to analyze the Phase II primary endpoint.","reportingStatus":"POSTED","timeFrame":"Evaluations occur every three months up to a year","title":"Tumor Response","type":"PRIMARY","unitOfMeasure":"participants"}